EP1007051A4 - Antagonistes du recepteur de l'integrine - Google Patents

Antagonistes du recepteur de l'integrine

Info

Publication number
EP1007051A4
EP1007051A4 EP98938357A EP98938357A EP1007051A4 EP 1007051 A4 EP1007051 A4 EP 1007051A4 EP 98938357 A EP98938357 A EP 98938357A EP 98938357 A EP98938357 A EP 98938357A EP 1007051 A4 EP1007051 A4 EP 1007051A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
integrin receptor
integrin
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98938357A
Other languages
German (de)
English (en)
Other versions
EP1007051A1 (fr
Inventor
Dirk Heerding
James Martin Samanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1007051A1 publication Critical patent/EP1007051A1/fr
Publication of EP1007051A4 publication Critical patent/EP1007051A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EP98938357A 1997-08-04 1998-08-04 Antagonistes du recepteur de l'integrine Withdrawn EP1007051A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5470397P 1997-08-04 1997-08-04
US54703P 1997-08-04
US6352697P 1997-10-29 1997-10-29
US63526P 1997-10-29
PCT/US1998/016246 WO1999006049A1 (fr) 1997-08-04 1998-08-04 Antagonistes du recepteur de l'integrine

Publications (2)

Publication Number Publication Date
EP1007051A1 EP1007051A1 (fr) 2000-06-14
EP1007051A4 true EP1007051A4 (fr) 2001-08-29

Family

ID=26733371

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98938357A Withdrawn EP1007051A4 (fr) 1997-08-04 1998-08-04 Antagonistes du recepteur de l'integrine

Country Status (5)

Country Link
EP (1) EP1007051A4 (fr)
JP (1) JP2001511452A (fr)
AU (1) AU8689798A (fr)
CA (1) CA2298544A1 (fr)
WO (1) WO1999006049A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2727746A1 (fr) 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company Medicaments antagonistes du recepteur de la vitronectine de quinolone
TR200101775T2 (tr) * 1998-12-18 2002-07-22 Dupont Pharmaceuticals Company Vitronektin alıcı antagonist farmasötikler
EP1140864A2 (fr) * 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Medicaments antagonistes du recepteur de la vitronectine
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2358855A1 (fr) 1999-02-03 2000-08-10 Merck & Co., Inc. Derives de la benzazepine utilises comme antagonistes du recepteur alpha-v de l'integrine
CO5180550A1 (es) * 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
JP2003506452A (ja) * 1999-08-06 2003-02-18 スミスクライン・ビーチャム・コーポレイション 発作の治療に有用なビトロネクチン受容体アンタゴニスト
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10028575A1 (de) * 2000-06-14 2002-03-14 Basf Ag Integrinliganden
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
DE10039998A1 (de) * 2000-08-11 2002-02-21 Basf Ag Neue substituierte Diareno-azepin-Derivate als Integrin Liganden
WO2001056995A1 (fr) 2000-01-18 2001-08-09 Nuerogen Corporation Imidazoles substitutes en tant que modulateurs selectifs des recepteurs de la bradykinine b¿2?
JP2004512345A (ja) * 2000-11-02 2004-04-22 スミスクライン・ビーチャム・コーポレイション 受容体アンタゴニスト−脂質コンジュゲートおよびそれを含有するデリバリービヒクル
WO2002085405A2 (fr) 2001-04-24 2002-10-31 Merck Patent Gmbh POLYTHERAPIE A BASE D'AGENTS ANTIANGIOGENIQUES ET DE FACTEUR DE NECROSE TUMORALE TNF$g(a)
EP1443963B1 (fr) 2001-10-22 2014-05-21 The Scripps Research Institute Composes de ciblage d'anticorps
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
CN101588812A (zh) 2007-01-18 2009-11-25 默克专利有限公司 使用整联蛋白配体治疗癌的特异疗法和药物
ES2457822T3 (es) 2007-11-08 2014-04-29 The General Hospital Corporation Procedimientos y composiciones de tratamiento de enfermedades proteinúricas
AU2008321770B2 (en) 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
EP2395992A2 (fr) 2009-02-10 2011-12-21 The Scripps Research Institute Vaccination programmée chimiquement
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
KR20220115062A (ko) 2021-02-09 2022-08-17 (주)오스티오뉴로젠 크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014776A2 (fr) * 1992-12-21 1994-07-07 Smithkline Beecham Corporation Antagonistes bicycliques du fibrinogene
WO1996000574A1 (fr) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Antagonistes du recepteur de la vibronectine
WO1996026190A1 (fr) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Antagonistes des recepteurs a l'integrine
WO1997001540A1 (fr) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Antagonistes du recepteur de l'integrine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0767792A4 (fr) * 1994-06-29 2002-11-20 Smithkline Beecham Corp Antagonistes du recepteur de la vitronectine
PL327694A1 (en) * 1995-12-29 1998-12-21 Smithkline Beecham Corp Antagonists of vitronectin receptor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014776A2 (fr) * 1992-12-21 1994-07-07 Smithkline Beecham Corporation Antagonistes bicycliques du fibrinogene
WO1996000574A1 (fr) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Antagonistes du recepteur de la vibronectine
WO1996026190A1 (fr) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Antagonistes des recepteurs a l'integrine
WO1997001540A1 (fr) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Antagonistes du recepteur de l'integrine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
RICHARD M. KEENAN ET AL.: "Discovery of potent nonpeptide Vitronectin Receptor (avb3) Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 40, no. 15, 18 July 1997 (1997-07-18), pages 2289 - 2292, XP002933333 *
See also references of WO9906049A1 *
WILLIAM E. BONDINELLI ET AL.: "Design of a potent and Orally active Nonpeptide platelet Fibrinogen Receptor (GPIIb/IIIa) Antagonist", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 2, no. 9, 1994, pages 897 - 908, XP000196285 *
WILLIAM H. MILLER ET AL.: "Structure-Activity Relationships in 3-oxo-1,4-benzodiazepine-2-acetic Acid GPIIb/IIIA antagonists. The 2-benzazepine series", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 6, no. 21, 1996, pages 2481 - 2486, XP004135899 *

Also Published As

Publication number Publication date
WO1999006049A1 (fr) 1999-02-11
JP2001511452A (ja) 2001-08-14
AU8689798A (en) 1999-02-22
CA2298544A1 (fr) 1999-02-11
EP1007051A1 (fr) 2000-06-14

Similar Documents

Publication Publication Date Title
EP1007051A4 (fr) Antagonistes du recepteur de l'integrine
EP1105389A4 (fr) Antagonistes de recepteurs d'integrine
CY2576B1 (en) Vitronectin receptor antagonists
IL133235A0 (en) 1-Amino-alkylcyclohexane nmda receptor antagonists
ZA9896B (en) Vitronectin receptor antagonists
IL135797A0 (en) Thrombin receptor antagonists
IL135028A0 (en) Vitronectin receptor antagonists
IL138245A0 (en) Vitronectin receptor antagonists
EP1027337A4 (fr) Antagonistes des recepteurs d'integrines
IL148043A0 (en) Novel integrin receptor antagonists
GB9820014D0 (en) Receptor antagonists and uses thereof
IL146146A0 (en) Integrin receptor antagonists
IL141163A0 (en) Vitronectin receptor antagonists
ZA9811500B (en) Integrin receptor antagonists
ZA986930B (en) Integrin receptor antagonists
IL119820A0 (en) Integrin receptor antagonists
GB9603373D0 (en) Integrin receptor antagonists
ZA988562B (en) Vitronectin receptor antagonists
ZA9610690B (en) Integrin receptor antagonists.
GB9811283D0 (en) Vironectin receptor antagonists
ZA964195B (en) Integrin receptor antagonists.
ZA9610873B (en) Integrin receptor antagonists.
HK1031115A (en) Vitronectin receptor antagonists
HK1026694A (en) Vitronectin receptor antagonists
GB9702834D0 (en) Fibrinogen receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20010712

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE ES FR GB IT LI NL

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/55 A, 7C 07D 223/16 B, 7C 07D 243/14 B, 7C 07D 267/14 B, 7C 07D 281/10 B, 7C 07D 401/14 B, 7C 07D 403/12 B

17Q First examination report despatched

Effective date: 20021023

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040720